Riken Genesis Co., Ltd., Amoy Diagnostics Co., Ltd. and Precision Medicine Asia Co., Ltd. announced that the Ministry of Health, Labour and Welfare (MHLW) has approved the AmoyDx®Pan Lung Cancer PCR Panel (the AmoyDx PLC Panel) as a companion diagnostic for TEPMETKO® (tepotinib) a Merck KGaA, Darmstadt, Germany product that received approval by the Japanese MHLW in March 2020. TEPMETKO (tepotinib) is approved for use in patients with unresectable, advanced or recurrent non-small cell lung cancer with MET gene exon 14 skipping alterations. The AmoyDx®PLC Panel is based on polymerase chain reaction (PCR) technology and can simultaneously evaluate the presence of 11 driver genes (EGFR/ALK/ROS1/KRAS/BRAF/HER2/RET/MET/NTRK1/NTRK2/NTRK3 genes) when all genes on the panel are approved as companion diagnostics. The AmoyDx®PLC Panel has received approval for five driver genes (EGFR, ALK, ROS1, BRAF, and MET exon 14 skipping) for ten associated targeted therapies in NSCLC. With its high sensitivity and short turnaround time, The AmoyDx®PLC Panel is expected to be an important clinical diagnostic in guiding treatment opportunities for NSCLC patients.